Core Insights - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [4] - The company announced the presentation of preclinical data for its GABAB positive allosteric modulator cough program at the 10th American Cough Conference [1][2] Company Overview - Addex's lead drug candidate is dipraglurant, a negative allosteric modulator targeting mGlu5, currently under evaluation for brain injury recovery [4] - The company is advancing an independent GABAB PAM program specifically for chronic cough, while also collaborating with Indivior on a GABAB PAM drug candidate for substance use disorders [4] - Addex holds a 20% equity interest in Neurosterix LLC, which is developing a portfolio of allosteric modulator programs for various neurological conditions [4] Presentation Details - The presentation will be led by Mikhail Kalinichev, Head of Translational Science, discussing the antitussive efficacy of Compound A in guinea pig models [2][3] - The presentation is scheduled for June 7, 2025, at 11:20 am EST [7] Scientific Background - GABAB receptors are crucial in the cough neural circuit and are activated by the neurotransmitter GABA [3] - Current treatments like baclofen have limitations, and targeting allosteric sites may offer advantages such as higher selectivity and better tolerability [3]

Core Insights - Addex Therapeutics announced that its partner Indivior has successfully advanced the GABAB positive allosteric modulator (PAM) program through IND enabling studies, marking the final preclinical development stage before clinical studies can commence [1][2] - Addex is eligible for payments up to USD 330 million based on the achievement of regulatory, clinical, and commercial milestones, along with tiered royalties on net sales ranging from high single digits to low double digits [2] Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [4] - The company's lead drug candidate, dipraglurant, is under evaluation for brain injury recovery, including post-stroke and traumatic brain injury recovery [4] - Addex holds a 20% equity interest in Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs for various neurological conditions [4] GABAB PAM Program - The GABAB PAM program is aimed at treating substance use disorders and has successfully completed preclinical safety and toxicity studies [2][3] - The activation of the GABAB receptor is clinically validated, with existing agonists like baclofen showing efficacy in multiple disease areas, although their use is limited due to side effects [3] - Novel PAMs are expected to provide efficacy with fewer adverse effects and less tolerance compared to direct agonists [3]